| Literature DB >> 32117009 |
Cira Fundarò1, Carlo Cavalieri2, Gian Domenico Pinna3, Anna Giardini4, Francesca Mancini5, Roberto Casale6.
Abstract
Background: In Parkinson's disease, reaching movements are conditioned by motor planning and execution deficiency. Recently, rehabilitation, aided by high technological devices, was employed for Parkinson's disease. Objective: We aimed to (1) investigate the changes in the upper limb motor performances in a sample of a patient with Parkinson's disease after a weightless training, with a passive exoskeleton, in an augmented-feedback environment; (2) highlight differences by motor parameters (performance, speed, and movement accuracy) and by type of movement (simple or complex); and (3) evaluate movement improvements by UPDRS II-III.Entities:
Keywords: Parkinson's disease; augmented feedback exercises; high technology rehabilitation; outcome measures; upper limb rehabilitation
Year: 2020 PMID: 32117009 PMCID: PMC7033477 DOI: 10.3389/fneur.2020.00040
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1Armeo Spring®, patient position in the mechanical arm support and horizontal movement (HC) are represented. Patients sit on a non-slip chair; the device is linked to a screen, placed at 1.5 m in front of the patient, allowing for simultaneous reproduction of movements performed by the patient; a photographic sequential representation of horizontal capture movement is also displayed. The patient depicted in the figures has provided consent to publish his image.
Figure 2Exercises for training described by plane of movement, joints involved, and progressive complexity of the exercises.
Description of the population and data results.
| NR | 20 | VC% | Right | 100 (90, 100) | 100 (95, 100) | 0 (0, 5) | 0.20 |
| Disease side onset | Left onset side 5 | VCa | Right | 1.27 ± 0.17 | 1.20 ± 0.09 | −0.06 ± 0.16 | 0.009 |
| Gender | M15; F5 | VCt | Right | 63.8 ± 17.0 | 52.6 ± 17.0 | −11.2 ± 15.8 | 0.006 |
| UPDRS II | 14.3 ± 5 (T0) | HC% | Right | 72 (61, 77) | 80 (77, 94) | 14 (0, 28) | 0.003 |
| UPDRS III | 29.1 ± 12.5 (T0) | HCa | Right | 1.44 ± 0.45 | 1.60 ± 0.29 | 0.15 ± 0.49 | 0.20 |
| Disease duration | 4.9 ± 2.2 | HCt | Right | 89.7 ± 21.6 | 76.6 ± 15.1 | −13.1 ± 14.9 | 0.002 |
| LED | 664.5 ± 240.9 | ||||||
The sample's clinical characteristics (gender, disease onset side, disease duration expressed in years, UPDRS II–III, levodopa daily total dosage LED expressed in mg) are reported; all the results are reported: data are expressed as mean ± SD (normally distributed data), or as median (lower quartile, upper quartile; non-normally distributed data). VC%, % of targets reached (ordinal number); VCa, trajectory accuracy (ordinal number); VCt, time execution test in seconds (s); HC%, % of targets reached (ordinal number); HCa, trajectory accuracy (ordinal number); HCt, time execution test in seconds (s).
Analysis was performed in 18 subjects owing to failure to execute the baseline evaluation in two subjects.
Figure 3Result representation (VCa, VCt at T0–T1, HC%, HCa, HCt at T0–T1) in both sides; the right side is represented with a circle and the left side with a square; in ordinate percentage of success completion expressed in %, trajectory accuracy expressed as ordinal number, total time execution expressed as seconds, and in abscissa the baseline and final time evaluation; VC% percentage of success completion is not represented (100% for the right and left sides at T0 and T1).